Aggregating multiple test results to improve medical decision-making
Table 3
Measured and error-corrected prevalence in Norrbotten, Sweden (May 25—June 5, 2020) [56].
The error correction method we employed takes into account the two tests used in the seroprevalence study from Norrbotten: (i) the Abbott SARS-CoV-2 IgG kit and (ii) the Euroimmun Anti-SARS-CoV-2 ELISA (IgG). These tests have been combined using an AND function. We calculated the measured, error-corrected prevalence through Eq (39) and their corresponding 95% CIs by generating 106 samples from beta distributions capturing the measured prevalence as well as the underlying individual test sensitivities and specificities. Details of the study are listed in the Materials and methods section.